

BORSA ITALIANA ORDERS ADMISSION OF THE ORDINARY SHARES OF PHARMANUTRA TO TRADING ON THE MTA - STAR SEGMENT

Trading start date 15th December 2020

Pisa, 11th December 2020 – [PharmaNutra S.p.A.](#) (the “**Company**” or “**PharmaNutra**”) (Aim Italia -Ticker PHN), nutraceutical company specialised in iron-based nutritional supplements and medical solutions for muscles and joints, communicates that Borsa Italiana S.p.A. (“**Borsa Italiana**”, Italian Stock Exchange) today ordered that trading of the ordinary shares of the Company (the “**Shares**”) on the *Mercato Telematico Azionario* “**MTA**”) should start from 15th December 2020.

In the same notice, *Borsa Italiana* assigned the STAR qualification to Company shares. From 15th December 2020, the Company Shares will be traded on the MTA - STAR Segment, and will be simultaneously excluded from trading on the AIM Italia market.

Please note that the Shares will keep the same ISIN code (IT0005274094) assigned on admission to the AIM Italia market.

The information prospectus on Company Shares being admitted to trading on the MTA - STAR Segment is available for the public in the Company’s registered office in Pisa, Via delle Lenze, 216/b and on its *website* www.pharmanutra.it, “Investor Relations” section.

The Company is assisted by: Mediobanca – Banca di Credito Finanziario S.p.A. as *Sponsor* for admission to trading on the MTA - STAR Segment; Gatti Pavesi Bianchi Studio Legale Associato is the legal adviser for the operation; BDO Italia S.p.A. is the auditing company.

Andrea Lacorte, President of PharmaNutra S.p.A., commented as follows: *“It is a great pleasure, and an honour, to celebrate PharmaNutra moving from the AIM Italia list to the STAR segment of Borsa Italiana, just three years after the first operation. This is a fundamental step for us; a key moment that will enable our company to benefit from a broader audience of international investors and, simultaneously, be more competitive and attractive in our sector. Entering the main market means compliance with those excellence requirements in transparency, corporate governance and liquidity terms, aspects that have always made PharmaNutra stand out. It wants to become a listed reference player for the market”.*

Roberto Lacorte, CEO of PharmaNutra, declares: *"This move to the STAR segment of the MTA market is an important step on a long value growth path that began with the Elite program, thanks to which the company was able to carry on developing in an excellent way. We are joining a market that PharmaNutra considers much more in line with and sensitive to its company business. This enables us to transfer the values accumulated during our growth drives in the best way possible"*

PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The effectiveness of its products is documented by considerable scientific proof. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of approximately 130 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 50 countries abroad, through 32 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL® brand, where it boasts a number of important patents on Sucrosomial® technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

PharmaNutra.it

For Information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b
56122 Pisa
Tel. +39 050 7846500
investorrelation@pharmanutra.it
Internal Press Office
press@calabughi.com

Press Office

Spriano Communication & Partners

Via Santa Radegonda, 16
20121 Milan
Tel. +39 02 83635708

Matteo Russo
mrusso@sprianocommunication.com
Cristina Tronconi
ctronconi@sprianocommunication.com